Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11151-6. doi: 10.1073/pnas.1401724111. Epub 2014 Jul 10.

Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers.

Author information

1
Laboratory of RNA Molecular Biology,Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065;
2
Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY 10032;
3
the Center for Clinical and Translational Science, and.
4
Department of Molecular Pharmacology and Physiology, Morsani College of Medicine, University of South Florida, Tampa, FL 33612; and.
5
Laboratory of RNA Molecular Biology,Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065;Program for Early and Recurrent Pregnancy Loss, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY 10461.
6
Laboratory of RNA Molecular Biology,Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065; ttuschl@rockefeller.edu pcs2121@cumc.columbia.edu.
7
Division of Cardiology, Department of Medicine, Columbia University Medical Center, New York, NY 10032; ttuschl@rockefeller.edu pcs2121@cumc.columbia.edu.

Abstract

Heart failure (HF) is associated with high morbidity and mortality and its incidence is increasing worldwide. MicroRNAs (miRNAs) are potential markers and targets for diagnostic and therapeutic applications, respectively. We determined myocardial and circulating miRNA abundance and its changes in patients with stable and end-stage HF before and at different time points after mechanical unloading by a left ventricular assist device (LVAD) by small RNA sequencing. miRNA changes in failing heart tissues partially resembled that of fetal myocardium. Consistent with prototypical miRNA-target-mRNA interactions, target mRNA levels were negatively correlated with changes in abundance for highly expressed miRNAs in HF and fetal hearts. The circulating small RNA profile was dominated by miRNAs, and fragments of tRNAs and small cytoplasmic RNAs. Heart- and muscle-specific circulating miRNAs (myomirs) increased up to 140-fold in advanced HF, which coincided with a similar increase in cardiac troponin I (cTnI) protein, the established marker for heart injury. These extracellular changes nearly completely reversed 3 mo following initiation of LVAD support. In stable HF, circulating miRNAs showed less than fivefold differences compared with normal, and myomir and cTnI levels were only captured near the detection limit. These findings provide the underpinning for miRNA-based therapies and emphasize the usefulness of circulating miRNAs as biomarkers for heart injury performing similar to established diagnostic protein biomarkers.

KEYWORDS:

body fluids; cardiovascular disease; development; exRNA; miRNA-mRNA regulation

PMID:
25012294
PMCID:
PMC4121804
DOI:
10.1073/pnas.1401724111
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center